MiR-125b regulates epithelial-mesenchymal transition via targeting Sema4C in paclitaxel-resistant breast cancer cells

Oncotarget

Volumn 6, Issue 5, 2015, Pages 3268-3279

  Yang, Qingling ^a   Wang, Yangyang ^a   Lu, Xiaohui ^a   Zhao, Zunlan ^a   Zhu, Lihua ^a   Chen, Sulian ^a   Wu, Qiong ^a   Chen, Changjie ^a   Wang, Zhiwei ^b  

^a BENGBU MEDICAL COLLEGE   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Breast cancer; EMT; Invasion; miR 125b; Paclitaxel

Indexed keywords

MICRORNA 125B; PACLITAXEL; PROTEIN SEMA4C; SEMAPHORIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MICRORNA; MIRN125 MICRORNA, HUMAN; SEMA4C PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER CELL; CANCER CONTROL; CANCER RESISTANCE; CHEMOSENSITIZATION; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MCF 7 PR CELL LINE; MESENCHYME CELL; PHENOTYPE; PROTEIN DEPLETION; PROTEIN RNA BINDING; PROTEIN TARGETING; REGULATORY MECHANISM; SKBR3 PR CELL LINE; UPREGULATION; BREAST NEOPLASMS; CELL MOTION; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; MCF-7 CELL LINE; METABOLISM; PATHOLOGY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR INVASION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL MOVEMENT; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; MICRORNAS; NEOPLASM INVASIVENESS; PACLITAXEL; RNA INTERFERENCE; SEMAPHORINS; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84923296705     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3065     Document Type: Article

References (55)

1. Chavez-MacGregor M and Gonzalez-Angulo AM. Breast cancer in 2012: New drugs, new knowledge, new targets. Nat Rev Clin Oncol. 2013; 10(2):75-76.
2. Siegel R, Ma J, Zou Z and Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64(1):9-29.
3. Zardavas D, Baselga J and Piccart M. Emerging targeted agents in metastatic breast cancer. Nat Rev Clin Oncol. 2013; 10(4):191-210.
4. Holohan C, Van Schaeybroeck S, Longley DB and Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013; 13(10):714-726.
5. Ali S and Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer. 2002; 2(2):101-112.
6. Thiery JP, Acloque H, Huang RY and Nieto MA. Epithelialmesenchymal transitions in development and disease. Cell. 2009; 139(5):871-890.
7. Izumchenko E, Chang X, Michailidi C, Kagohara L, Ravi R, Paz K, Brait M, Hoque M, Ling S, Bedi A and Sidransky D. The TGFbeta-miR200-MIG6 pathway orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitors. Cancer Res. 2014; 74(14):3995-4005.
8. Wilson C, Nicholes K, Bustos D, Lin E, Song Q, Stephan JP, Kirkpatrick DS and Settleman J. Overcoming EMTassociated resistance to anti-cancer drugs via Src/FAK pathway inhibition. Oncotarget. 2014; 5(17):7328-7341.
9. Xiong X, Arvizo RR, Saha S, Robertson DJ, McMeekin S, Bhattacharya R and Mukherjee P. Sensitization of ovarian cancer cells to cisplatin by gold nanoparticles. Oncotarget. 2014; 5(15):6453-6465.
10. Kajiyama H, Shibata K, Terauchi M, Yamashita M, Ino K, Nawa A and Kikkawa F. Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol. 2007; 31(2):277-283.
11. Du F, Wu X, Liu Y, Wang T, Qi X, Mao Y, Jiang L, Zhu Y, Chen Y, Zhu R, Han X, Jin J, Ma X and Hua D. Acquisition of paclitaxel resistance via PI3K dependent epithelial mesenchymal transition in A2780 human ovarian cancer cells. Oncol Rep. 2013; 30(3):1113-1118.
12. Moisan F, Francisco EB, Brozovic A, Duran GE, Wang YC, Chaturvedi S, Seetharam S, Snyder LA, Doshi P and Sikic BI. Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers. Mol Oncol. 2014; 8(7):1231-1239.
13. Chen SY, Hu SS, Dong Q, Cai JX, Zhang WP, Sun JY, Wang TT, Xie J, He HR, Xing JF, Lu J and Dong YL. Establishment of Paclitaxel-resistant Breast Cancer Cell Line and Nude Mice Models, and Underlying Multidrug Resistance Mechanisms in Vitro and in Vivo. Asian Pac J Cancer Prev. 2013; 14(10):6135-6140.
14. Yang Q, Huang J, Wu Q, Cai Y, Zhu L, Lu X, Chen S, Chen C and Wang Z. Acquisition of epithelialmesenchymal transition is associated with Skp2 expression in paclitaxel-resistant breast cancer cells. Br J Cancer. 2014; 110(8):1958-1967.
15. Fang L, Li H, Wang L, Hu J, Jin T, Wang J and Yang BB. MicroRNA-17-5p promotes chemotherapeutic drug resistance and tumour metastasis of colorectal cancer by repressing PTEN expression. Oncotarget. 2014; 5(10):2974- 2987.
16. Wang Z, Wang N, Liu P, Chen Q, Situ H, Xie T, Zhang J, Peng C, Lin Y and Chen J. MicroRNA-25 regulates chemoresistance-associated autophagy in breast cancer cells, a process modulated by the natural autophagy inducer isoliquiritigenin. Oncotarget. 2014; 5(16):7013-7026.
17. Jiang L, He D, Yang D, Chen Z, Pan Q, Mao A, Cai Y, Li X, Xing H, Shi M, Chen Y, Bruce IC, Wang T, Jin L, Qi X, Hua D, et al. MiR-489 regulates chemoresistance in breast cancer via epithelial mesenchymal transition pathway. FEBS Lett. 2014; 588(11):2009-2015.
18. Ward A, Balwierz A, Zhang JD, Kublbeck M, Pawitan Y, Hielscher T, Wiemann S and Sahin O. Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer. Oncogene. 2013; 32(9):1173-1182.
19. Chen Y, Sun Y, Chen L, Xu X, Zhang X, Wang B, Min L and Liu W. miRNA-200c increases the sensitivity of breast cancer cells to doxorubicin through the suppression of E-cadherin-mediated PTEN/Akt signaling. Mol Med Rep. 2013; 7(5):1579-1584.
20. Bai WD, Ye XM, Zhang MY, Zhu HY, Xi WJ, Huang X, Zhao J, Gu B, Zheng GX, Yang AG and Jia LT. MiR-200c suppresses TGF-beta signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer. International journal of cancer. 2014; 135(6):1356-1368.
21. Manavalan TT, Teng Y, Litchfield LM, Muluhngwi P, Al-Rayyan N and Klinge CM. Reduced expression of miR- 200 family members contributes to antiestrogen resistance in LY2 human breast cancer cells. PLoS One. 2013; 8(4):e62334.
22. Wang HJ, Guo YQ, Tan G, Dong L, Cheng L, Li KJ, Wang ZY and Luo HF. miR-125b regulates side population in breast cancer and confers a chemoresistant phenotype. J Cell Biochem. 2013; 114(10):2248-2257.
23. Banzhaf-Strathmann J and Edbauer D. Good guy or bad guy: the opposing roles of microRNA 125b in cancer. Cell communication and signaling. 2014; 12:30.
24. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Menard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005; 65(16):7065-7070.
25. Hui AB, Shi W, Boutros PC, Miller N, Pintilie M, Fyles T, McCready D, Wong D, Gerster K, Waldron L, Jurisica I, Penn LZ and Liu FF. Robust global micro-RNA profiling with formalin-fixed paraffin-embedded breast cancer tissues. Lab Invest. 2009; 89(5):597-606.
26. Berber U, Yilmaz I, Narli G, Haholu A, Kucukodaci Z and Demirel D. miR-205 and miR-200c: Predictive Micro RNAs for Lymph Node Metastasis in Triple Negative Breast Cancer. J Breast Cancer. 2014; 17(2):143-148.
27. Calvano Filho CM, Calvano-Mendes DC, Carvalho KC, Maciel GA, Ricci MD, Torres AP, Filassi JR and Baracat EC. Triple-negative and luminal A breast tumors: differential expression of miR-18a-5p, miR-17-5p, and miR-20a-5p. Tumour Biol. 2014; 35(8):7733-7741.
28. Ferracin M, Bassi C, Pedriali M, Pagotto S, D'Abundo L, Zagatti B, Corra F, Musa G, Callegari E, Lupini L, Volpato S, Querzoli P and Negrini M. miR-125b targets erythropoietin and its receptor and their expression correlates with metastatic potential and ERBB2/HER2 expression. Mol Cancer. 2013; 12(1):130.
29. Feliciano A, Castellvi J, Artero-Castro A, Leal JA, Romagosa C, Hernandez-Losa J, Peg V, Fabra A, Vidal F, Kondoh H, Ramon YCS and Lleonart ME. miR-125b acts as a tumor suppressor in breast tumorigenesis via its novel direct targets ENPEP, CK2-alpha, CCNJ, and MEGF9. PLoS One. 2013; 8(10):e76247.
30. Mar-Aguilar F, Luna-Aguirre CM, Moreno-Rocha JC, Araiza-Chavez J, Trevino V, Rodriguez-Padilla C and Resendez-Perez D. Differential expression of miR-21, miR- 125b and miR-191 in breast cancer tissue. Asia Pac J Clin Oncol. 2013; 9(1):53-59.
31. Scott GK, Goga A, Bhaumik D, Berger CE, Sullivan CS and Benz CC. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem. 2007; 282(2):1479-1486.
32. Rajabi H, Jin C, Ahmad R, McClary C, Joshi MD and Kufe D. MUCIN 1 Oncoprotein expression is suppressed by the miR-125b oncomiR. Genes Cancer. 2010; 1(1):62-68.
33. Zhang Y, Yan LX, Wu QN, Du ZM, Chen J, Liao DZ, Huang MY, Hou JH, Wu QL, Zeng MS, Huang WL, Zeng YX and Shao JY. miR-125b is methylated and functions as a tumor suppressor by regulating the ETS1 proto-oncogene in human invasive breast cancer. Cancer Res. 2011; 71(10):3552-3562.
34. Akhavantabasi S, Sapmaz A, Tuna S and Erson-Bensan AE. miR-125b targets ARID3B in breast cancer cells. Cell Struct Funct. 2012; 37(1):27-38.
35. Komagata S, Nakajima M, Takagi S, Mohri T, Taniya T and Yokoi T. Human CYP24 catalyzing the inactivation of calcitriol is post-transcriptionally regulated by miR-125b. Mol Pharmacol. 2009; 76(4):702-709.
36. Tang F, Zhang R, He Y, Zou M, Guo L and Xi T. MicroRNA-125b induces metastasis by targeting STARD13 in MCF-7 and MDA-MB-231 breast cancer cells. PLoS One. 2012; 7(5):e35435.
37. Zhou QD, Ning Y, Zeng R, Chen L, Kou P, Xu CO, Pei GC, Han M and Xu G. Erbin interacts with Sema4C and inhibits Sema4C-induced epithelial-mesenchymal transition in HK2 cells. J Huazhong Univ Sci Technolog Med Sci. 2013; 33(5):672-679.
38. Zeng R, Han M, Luo Y, Li C, Pei G, Liao W, Bai S, Ge S, Liu X and Xu G. Role of Sema4C in TGF-beta1-induced mitogen-activated protein kinase activation and epithelialmesenchymal transition in renal tubular epithelial cells. Nephrology, dialysis, transplantation. 2011; 26(4):1149- 1156.
39. Ye SM, Han M, Kan CY, Yang LL, Yang J, Ma QF and Wang SX. Expression and clinical significance of Sema4C in esophageal cancer, gastric cancer and rectal cancer. Zhonghua Yi Xue Za Zhi. 2012; 92(28):1954-1958.
40. Jiang JX, Gao S, Pan YZ, Yu C and Sun CY. Overexpression of microRNA-125b sensitizes human hepatocellular carcinoma cells to 5-fluorouracil through inhibition of glycolysis by targeting hexokinase II. Mol Med Rep. 2014; 10(2):995-1002.
41. Zhou L, Bai H, Wang C, Wei D, Qin Y and Xu X. microRNA125b promotes leukemia cell resistance to daunorubicin by inhibiting apoptosis. Mol Med Rep. 2014; 9(5):1909-1916.
42. Chen J, Fu X, Wan Y, Wang Z, Jiang D and Shi L. miR- 125b inhibitor enhance the chemosensitivity of glioblastoma stem cells to temozolomide by targeting Bak1. Tumour Biol. 2014; 35(7):6293-6302.
43. Shi L, Wan Y, Sun G, Zhang S, Wang Z and Zeng Y. miR- 125b inhibitor may enhance the invasion-prevention activity of temozolomide in glioblastoma stem cells by targeting PIAS3. BioDrugs. 2014; 28(1):41-54.
44. Shi L, Zhang S, Feng K, Wu F, Wan Y, Wang Z, Zhang J, Wang Y, Yan W, Fu Z and You Y. MicroRNA-125b-2 confers human glioblastoma stem cells resistance to temozolomide through the mitochondrial pathway of apoptosis. Int J Oncol. 2012; 40(1):119-129.
45. Akbari Moqadam F, Lange-Turenhout EA, Aries IM, Pieters R and den Boer ML. MiR-125b, miR-100 and miR- 99a co-regulate vincristine resistance in childhood acute lymphoblastic leukemia. Leuk Res. 2013; 37(10):1315- 1321.
46. Zhang H, Luo XQ, Feng DD, Zhang XJ, Wu J, Zheng YS, Chen X, Xu L and Chen YQ. Upregulation of microRNA- 125b contributes to leukemogenesis and increases drug resistance in pediatric acute promyelocytic leukemia. Mol Cancer. 2011; 10:108.
47. Iida K, Fukushi J, Matsumoto Y, Oda Y, Takahashi Y, Fujiwara T, Fujiwara-Okada Y, Hatano M, Nabashima A, Kamura S and Iwamoto Y. miR-125b develops chemoresistance in Ewing sarcoma/primitive neuroectodermal tumor. Cancer Cell Int. 2013; 13(1):21.
48. Manfe V, Biskup E, Willumsgaard A, Skov AG, Palmieri D, Gasparini P, Lagana A, Woetmann A, Odum N, Croce CM and Gniadecki R. cMyc/miR-125b-5p signalling determines sensitivity to bortezomib in preclinical model of cutaneous T-cell lymphomas. PLoS One. 2013; 8(3):e59390.
49. Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G and Ferlini C. Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol. 2008; 111(3):478-486.
50. Chen S, Zhu L, Huang J, Cai Y, Lu X, Yang Q, Wu Q, Chen C and Wang Z. Arsenic trioxide targets miR-125b in glioma cells. Curr Pharm Des. 2014; 20(33):5354-5361.
51. Hofmann MH, Heinrich J, Radziwill G and Moelling K. A short hairpin DNA analogous to miR-125b inhibits C-Raf expression, proliferation, and survival of breast cancer cells. Mol Cancer Res. 2009; 7(10):1635-1644.
52. Wang S, Huang J, Lyu H, Lee CK, Tan J, Wang J and Liu B. Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/ erbB3 and apoptosis in breast cancer cells. Cell Death Dis. 2013; 4:e556.
53. Wu Q, Wang R, Yang Q, Hou X, Chen S, Hou Y, Chen C, Yang Y, Miele L, Sarkar FH, Chen Y and Wang Z. Chemoresistance to gemcitabine in hepatoma cells induces epithelial-mesenchymal transition and involves activation of PDGF-D pathway. Oncotarget. 2013; 4(11):1999-2009.
54. Tan Y, Qin S, Hou X, Qian X, Xia J, Li Y, Wang R, Chen C, Yang Q, Miele L, Wu Q and Wang Z. Proteomicbased analysis for identification of proteins involved in 5-fluorouracil resistance in hepatocellular carcinoma. Curr Pharm Des. 2014; 20(1):81-87.
55. Wang R, Cheng L, Xia J, Wang Z and Wu Q. Gemcitabine resistance is associated with epithelial-mesenchymal transition and induction of HIF-1alpha in pancreatic cancer cells. Curr Cancer Drug Targets. 2014; 14(4):407-417.